로딩 중…
지수 로딩 중…
지에프씨생명과학
388610· KOSDAQ· Financials· Diversified Financials
₩5,900-5.45%
2026-06-19
Price Chart
지에프씨생명과학-75.82%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 31.42B KRW |
| Revenue | 17.71B KRW |
| Net Income | 555.4M KRW |
| Total Assets | 33.83B KRW |
| Net Assets | 23.80B KRW |
| Employees | 80 |
| Value | |
| P/E | 56.57x |
| P/B | 1.32x |
| P/S | 1.77x |
| EV/EBITDA | 64.80x |
| FCF Yield | -13.69% |
| Profitability | |
| ROE | 2.33% |
| ROA | 1.64% |
| Op. Margin | 2.18% |
| Revenue Growth | 5.42% |
| Financial Health | |
| Debt Ratio | 42.16% |
| Total Debt | 6.98B KRW |
| FCF | -4.30B KRW |
| Cash | 7.47B KRW |
| Current Ratio | 5.60x |
| Net Debt/EBITDA | -1.02x |
| Performance | |
| 1Y Return | -75.82% |
| 1M Return | -19.18% |
| From 52W High | -85.25% |
| 1Y MDD | -81.97% |
| Trading | |
| Volume | 12,456 shares |
| Foreign Own. | 2.69% |
| Per Share | |
| EPS | 145 KRW |
| BPS | 4,653 KRW |
Company Info
GFC Life Science, established in 2002, listed on KONEX in 2022 and transferred to KOSDAQ in 2025. The company specializes in developing and producing cosmetic biomaterials using skin microbiome and exosome technologies, alongside providing efficacy testing and advertising substantiation data for functional cosmetics. Leveraging a library of over 2,000 strains, more than 80 patented microorganisms, and patented exosome isolation and purification technology, it is actively developing skin booster products and pursuing global market expansion. GFC Life Science is headquartered in Hwaseong-si, Gyeonggi-do.